Impact of switching from the originator adalimumab to a biosimilar: a retrospective cohort study

Abstract Introduction Adalimumab is a monoclonal antibody that is used to treat autoimmune and inflammatory diseases. Biosimilars for adalimumab, including Hyrimoz, have been developed. We aimed to evaluate the effectiveness and adverse effects of Hyrimoz after switching. Methods The cohort consiste...

Full description

Bibliographic Details
Published in:	BMC Immunology
Main Authors:	W. H. A. van Poecke, N. E. F. Hooi, T. K. Mossel, M. A. W. Hermans, P. L. A. van Daele, E. M. Bunnik, Z. Brkic, L. K. Sels, A. A. H. J. Thiadens, P. M. van Hagen, J. A. M. van Laar, S. M. Rombach
Format:	Article
Language:	English
Published:	BMC 2025-07-01
Subjects:	Flare adverse effects biosimilar adalimumab Hyrimoz Humira
Online Access:	https://doi.org/10.1186/s12865-025-00693-9

Similar Items

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
by: Ioana Gherghescu, et al.
Published: (2020-12-01)

NMR-based structural integrity analysis of therapeutic monoclonal antibodies: a comparative study of Humira and its biosimilars
by: Donna Baldisseri, et al.
Published: (2025-12-01)

Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective Study
by: Martina Burlando, et al.
Published: (2022-10-01)

Cost per responder of adalimumab biosimilars versus methotrexate in patients with psoriasis: a real-life experience
by: Martina Maurelli, et al.
Published: (2023-12-01)

Iraqi Registry Data Proves Safety and Efficacy of switching to Adalimumab Biosimilar in Treating Rheumatoid Arthritis
by: Yasameen Abbas, et al.
Published: (2024-12-01)

Efficacy and safety evaluations of adalimumab biosimilars in the treatment of psoriasis
by: Changkun Li, et al.
Published: (2023-12-01)

Comparative efficacy and safety of adalimumab biosimilar (BCD-057) and innovator in patients with psoriasis vulgaris. Results of the BCD-057-2/CALYPSO phase III international, multicenter, randomized double-blind clinical trial
by: Т. V. Korotaeva, et al.
Published: (2018-12-01)

Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis
by: Vandana Midha, et al.
Published: (2018-01-01)

Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study
by: Giammarco Mocci, et al.
Published: (2022-07-01)

Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double‐blind, parallel‐controlled, phase 1 study
by: Hong Zhang, et al.
Published: (2021-04-01)

A prospective, randomized, double-blind, comparative clinical study of efficacy and safety of a biosimilar adalimumab with innovator product in patients with active rheumatoid arthritis on a stable dose of methotrexate
by: Prasad Apsangikar, et al.
Published: (2018-01-01)

Efficacy of switching from originator adalimumab to biosimilar adalimumab-AACF in patients with axial spondyloarthritis: a 12-month observational study
by: Fanny Alcira Reyes Neira, et al.
Published: (2025-02-01)

Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy
by: Marco May Lee, et al.
Published: (2025-07-01)

Severe paradoxical generalized pustular psoriasis induced by adalimumab biosimilar successfully treated with brodalumab
by: Angela Fico, et al.
Published: (2025-05-01)

Navigating adalimumab biosimilars: an expert opinion
by: Vered Abitbol, et al.
Published: (2023-10-01)

Adalimumab Biosimilars Demonstrate Long-Term Durability and Cost-Effectiveness in Paediatric Inflammatory Bowel Disease: A Real-World Two-Centre European Cohort Study
by: Ancona S, et al.
Published: (2025-04-01)

Efficacy of switching from originator adalimumab to biosimilar adalimumab-AACF in patients with rheumatoid arthritis: a 12-month observational study
by: Fanny Reyes-Neira, et al.
Published: (2025-10-01)

A comprehensive evaluation of the transition to a biosimilar of adalimumab in rheumatoid arthritis and psoriatic arthritis: a single-center experience with a focus on imaging outcomes
by: Rodrigo Garcia-Salinas, et al.
Published: (2025-05-01)

Comparison of Efficacy and Safety of Original and Biosimilar Adalimumab in Active Rheumatoid Arthritis in a Real-World National Cohort
by: Claudiu Costinel Popescu, et al.
Published: (2022-12-01)

CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study
by: David M. Pariser, et al.
Published: (2025-03-01)

Comparison of two biosimilarity studies of FKB327 with the adalimumab reference product: randomized phase 1 studies of single-blind, single-dose subcutaneous injection in healthy Japanese male participants
by: Takuma Yonemura, et al.
Published: (2022-01-01)

A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis
by: Ahmadreza Jamshidi, et al.
Published: (2017-07-01)

Transition from reference adalimumab to biosimilar SB5 in patients with rheumatoid arthritis: sub-analysis of Spanish patients in the PROPER study
by: Fernando Pérez-Ruiz, et al.
Published: (2025-02-01)

Effect of treatment with original or biosimilar adalimumab on SARS-CoV2 vaccination antibody titers
by: Eva Dokoupilová, et al.
Published: (2024-06-01)

Treatment Persistence and Switching Patterns of Adalimumab Biosimilar ABP 501 in European Patients with Rheumatologic Diseases
by: Ran Jin, et al.
Published: (2024-03-01)

Biosimilars in Focus: Evaluating Their Role Compared to Adalimumab in Clinical Practice
by: Dorota Waz, et al.
Published: (2025-01-01)

Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars
by: Ali M. Alsamil, et al.
Published: (2021-02-01)

Anti-Adalimumab Antibodies Purified from Juvenile Idiopathic Arthritis Patients: Kinetic Characterization Among Biosimilars
by: Andrea Di Santo, et al.
Published: (2025-04-01)

Outcomes Following Adalimumab Bio-originator to Biosimilar Switch—A Comparison Using Real-world Patient- and Physician-Reported Data in European Countries
by: Peter C. Taylor, et al.
Published: (2023-01-01)

Effects of Adalimumab-adbm Versus Adalimumab Reference Product on Patient-Reported Outcomes in Rheumatoid Arthritis: Results from VOLTAIRE-RA
by: Vibeke Strand, et al.
Published: (2024-08-01)

Self‐Injection Satisfaction and Safety of CT‐P17 (Yuflyma), a High‐Concentration Adalimumab Biosimilar, in Patients With Crohn's Disease: A Cross‐Sectional Study
by: Fei Yang Pan, et al.
Published: (2025-08-01)

Summary of Research: Effects of Adalimumab-adbm Versus Adalimumab Reference Product on Patient-Reported Outcomes in Rheumatoid Arthritis: Results from VOLTAIRE-RA
by: Vibeke Strand
Published: (2024-08-01)

Efficacy and safety of adalimumab biosimilar (HS016) in inflammatory bowel disease from the real-world study
by: Fang Wang, et al.
Published: (2023-10-01)

Adalimumab biosimilar ABP 501 is equally effective and safe in long-term management of inflammatory bowel diseases patients when used as first biologic treatment or as replace of the ADA originator for a non-medical reason
by: Giammarco Mocci, et al.
Published: (2023-10-01)

Volume and trends of adalimumab and pembrolizumab reimbursed market: the Bulgarian perspective
by: Maria Kamusheva, et al.
Published: (2021-01-01)

Real-World Experience with an Adalimumab Biosimilar (ABP 501) in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis in Europe: Results from the Adelphi Disease Specific Programme
by: Ran Jin, et al.
Published: (2025-03-01)

Case report: Area of focus of management of severe pityriasis rubra pilaris by dose optimization of adalimumab biosimilar in combination with acitretin and montelukast
by: Kristine Heidemeyer, et al.
Published: (2023-11-01)

Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for a systematic review and meta-analysis
by: Bruna O. Ascef, et al.
Published: (2021-07-01)

Highly effective treatment options for rheumatoid arthritis afforded by the availability of biosimilars
by: Leticia A. Shea, et al.
Published: (2025-03-01)

Switching Among Biosimilars: A Review of Clinical Evidence
by: Eleonora Allocati, et al.
Published: (2022-08-01)